1 |
breast cancer resistance protein
(1308 times)
|
Pharmacology (498 times)
|
P-gp (508 times) ABC (174 times) MRP2 (119 times)
|
1998 A multidrug resistance transporter from human MCF-7 breast cancer cells.
|
2 |
breast cancer-related protein
(8 times)
|
Medicine (2 times)
|
P-gp (4 times) ABC (2 times) BBB (2 times)
|
2006 Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies.
|
3 |
BCRP/MXR/ABCP
(2 times)
|
Neoplasms (2 times)
|
---
|
2001 Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
|
4 |
breast cancer receptor protein
(2 times)
|
Pharmacology (2 times)
|
ABC (1 time) AP (1 time) app (1 time)
|
2007 Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers.
|
5 |
Breast Cancer Research Program
(2 times)
|
Gynecology (1 time)
|
BC (1 time) BCRF (1 time) DoD (1 time)
|
2005 Perspective from the Department of Defense Breast Cancer Research Program.
|
6 |
Baltimore Cancer Research Program
(1 time)
|
Neoplasms (1 time)
|
ANLL (1 time)
|
1987 Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.
|
7 |
BCRP substrates
(1 time)
|
Molecular Biology (1 time)
|
Fni,7.0 (1 time) fup (1 time) GMFE (1 time)
|
2022 Developing an In Vitro to In Vivo Extrapolation (IVIVE) Model to Predict Human Milk-to-Plasma Drug Concentration Ratios.
|
8 |
benign colorectal polyps
(1 time)
|
Neoplasms (1 time)
|
CRC (1 time) NPV (1 time) PPV (1 time)
|
2022 The role of microvesicles as biomarkers in the screening of colorectal neoplasm.
|
9 |
Boston Combined Residency Program
(1 time)
|
Clinical Medicine (1 time)
|
UIM (1 time)
|
2022 Implementing and Assessing a Resident Diversity Council to Address the Need for a Diverse Clinical Workforce.
|
10 |
Breakpoint Cluster Region pseudogene
(1 time)
|
Genetics, Medical (1 time)
|
22q11.2DS (1 time) Mb (1 time) WGS (1 time)
|
2016 Variant discovery and breakpoint region prediction for studying the human 22q11.2 deletion using BAC clone and whole genome sequencing analysis.
|
11 |
Breast Cancer Resistance Peptide
(1 time)
|
Pharmacy (1 time)
|
---
|
2010 ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
|
12 |
breast cancer resistance protein substrate
(1 time)
|
Pharmacology (1 time)
|
AUC (1 time) EGFR (1 time) GLSM (1 time)
|
2018 Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
|
13 |
Breast cancer risk perception
(1 time)
|
Public Health (1 time)
|
BCRAF (1 time) GRM (1 time)
|
2017 A Risk Assessment Comparison of Breast Cancer and Factors Affected to Risk Perception of Women in Turkey: A Cross-sectional Study.
|
14 |
breast cancer therapy-resistant protein
(1 time)
|
Biochemistry (1 time)
|
5'-RACE (1 time) 5-FU (1 time) DPYD (1 time)
|
2020 Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
|
15 |
bromocriptine-resistant prolactinomas
(1 time)
|
Neurology (1 time)
|
ER (1 time) WIF1 (1 time)
|
2013 Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
|